How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today’s clinicians.

Pseudomonas aeruginosa chronic infections in patients with bronchiectasis: a silent reservoir of carbapenemase-producing epidemic high-risk clones.

Addressing carbapenemase-producing extensively drug-resistant Pseudomonas aeruginosa: the potential of cefiderocol and ceftazidime/avibactam plus aztreonam therapy.

Comparative analysis of acute respiratory infections of viral etiology in children under 6 months with and without nirsevimab in the Balearic Islands (2022-2023 and 2023-2024).

Synergistic efficacy of ceftazidime/avibactam and aztreonam against carbapenemase-producing Pseudomonas aeruginosa: insights from the hollow-fiber infection model.